AIDS Malignancy Consortium (AMC)

 描述(由申请人提供)：艾滋病恶性联盟(AMC)成立于1995年，一直处于艾滋病毒恶性肿瘤治疗和预防干预措施的临床评估的前沿，并在其临床试验的背景下研究艾滋病毒癌症的生物学。自那时以来，AMC已经进行了96项临床试验、调查和实验室研究，涉及3484名艾滋病毒相关癌症患者，并发表了关于艾滋病恶性肿瘤的各种主题。AMC研究中出现的几项关键科学发现改善了患者的治疗或管理，并帮助建立了其中几种肿瘤的当前护理标准，包括卡波西氏肉瘤、非霍奇金淋巴瘤、肛门癌和肛门上皮内瘤变。此外，AMC在新的靶向癌症疗法与抗逆转录病毒疗法联合使用的药代动力学评估方面处于领先地位，这有助于确定这些药物在联合使用时的安全剂量。AMC还在撒哈拉以南非洲进行艾滋病毒相关癌症的临床试验，那里艾滋病毒和癌症的流行已经大幅增长。美国许多艾滋病恶性疾病的关键临床和实验室研究人员的参与使AMC成为世界上致力于改善这一人群癌症治疗和预防的主要临床试验组织。我们建议继续和扩大我们在这些领域的国内和国际临床试验工作，包括锚定试验，这是一项大型随机对照研究，调查高级别肛门鳞状上皮内病变的常规肛门筛查和干预在预防HIV肛门癌方面的作用，该疾病的发病率最近迅速上升。

 DESCRIPTION (provided by applicant): The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in HIV and in studying the biology of cancers in HIV in the context of its clinical trials. Since that time the AMC has conducted 96 clinical trials surveys and laboratory studies involving 3484 patients with HIV-associated cancers and published on a wide variety of topics in AIDS malignancies. Several key scientific findings that emerged from AMC studies have led to improvements in the treatment or management of patients and have helped establish the current standard of care for several of these tumors, including Kaposi's sarcoma, non-Hodgkin's lymphoma, anal cancer and anal intraepithelial neoplasia. In addition, the AMC is a leader in the pharmacokinetic assessment of new targeted cancer therapies in conjunction with antiretroviral therapy, which has helped define safe doses of these drugs when used in combination. The AMC is also conducting clinical trials in HIV-associated cancers in sub-Saharan Africa where the epidemic of HIV and cancer has grown substantially. The participation of many of the key clinical and laboratory researchers in AIDS malignancies in the USA has made the AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial, a large randomized controlled study investigating the role of routine anal screening and intervention for high-grade anal squamous intraepithelial lesions for the prevention of anal cancer in HIV, which has rapidly increased in incidence recently.